-Eurofins Discovery, an industry-leading provider of products and services for drug discovery research, announced the launch of DiscoveryAI SAFIRE (Suite o...
Fresenius Kabi announced it has introduced Cyclophosphamide for Injection, USP, a generic substitute for Cytoxan, for use in treating several forms o...
Curve Therapeutics, a pioneering biotechnology firm, announced a significant £40.5 million Series A funding round, led by Pfizer Ventures and joined ...
Bristol Myers Squibb (NYSE: BMY) announced that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB). With the completion of the ...
Fujifilm Irvin Technology is a leader in the innovation and manufacturing of cell culture solutions in the global life sciences and medical markets. With t...
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimil...
In a significant breakthrough for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), Boehringer Ingelheim's latest Phase II clinical...
Sanofi-Aventis Groupe announced promising results from its Phase 2 RILECSU study, showcasing rilzabrutinib's ability to significantly reduce itch severity ...
In a bold move, Vaccinex has forged eight new antibody discovery agreements with leading pharmaceutical and biotechnology companies, as well as str...
Pfizer Inc. has announced that the European Commission (EC) has granted marketing authorization for VELSIPITY® (etrasimod) in the European Union, marki...
ChatGPT CAMBRIDGE, Mass.--(BUSINESS WIRE)--February 16, 2024 07:00 AM Eastern Standard Time Sarepta Therapeutics, Inc. (NASDAQ:...
Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a pioneering oncology biopharmaceutical company, has revealed prom...
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have announced the acceptance of their Biologics License Application (BLA) for datopotamab...
Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved...
© 2025 Biopharma Boardroom. All Rights Reserved.
